<i>APOE</i> ε4 genotyping for populational enrichment of tau‐targeting clinical trials in cognitively impaired individuals
Our results support that using APOEε4 genotype together with Aβ positivity for population enrichment to select individuals at higher risk of fast tau accumulation could potentially reduce required sample sizes and costs for tau-targeting trials focusing on CI individuals. Hence, this may be a cost-effective strategy.
Authors
- Douglas Teixeira Leffa (ORCID: https://orcid.org/0000-0002-4890-8451)
- Nesrine Rahmouni
- Wagner S. Brum (ORCID: https://orcid.org/0000-0002-9777-0559)
- Laura Rosso (ORCID: https://orcid.org/0000-0002-0304-5840)
- Firoza Zubeida Lussier (ORCID: https://orcid.org/0000-0002-6877-4825)
- Andrei Bieger (ORCID: https://orcid.org/0000-0002-6669-2834)
- Cristiano Schaffer Aguzzoli (ORCID: https://orcid.org/0000-0002-7378-3830)
- Pamela C.L. Ferreira
- João Pedro Ferrari‐Souza
- Arthur Macedo
- Eduardo R. Zimmer
- Lucas Bastos Beltrami
- Joseph Therriault
- Bruna Bellaver
- Giovanna Carello‐Collar
- Marco De Bastiani
- Diogo O. Souza
- Guilherme Povala
- Wyllians Vendramini Borelli
- Pedro Rosa‐Neto
Institutions
- Universidade Federal do Rio Grande do Sul (BR)
- University of Pittsburgh (US)
- Hospital São Lucas da PUCRS (BR)
- McGill University (CA)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_107470
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00